888-969-2592
Kalkine 0
countryflagCA

Nektar Therapeutics

Healthcare US NKTR

8.84USD
-1.15(11.51%)

Last update at 2025-06-09T18:52:00Z

Day Range

8.7611.02
LowHigh

52 Week Range

0.411.93
LowHigh

Fundamentals

  • Previous Close 9.99
  • Market Cap275.44M
  • Volume622919
  • P/E Ratio-
  • Dividend Yield-%
  • EBITDA-125.54100M
  • Revenue TTM90.17M
  • Revenue Per Share TTM0.47
  • Gross Profit TTM 70.42M
  • Diluted EPS TTM-0.91

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Analyst Recommendations

Financials

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Income before tax -364.98300M -523.28000M -443.94700M -440.05400M 682.73M
Minority interest - - - - -
Net income -368.19800M -523.83700M -444.44000M -440.66700M 681.31M
Selling general administrative 92.33M 122.84M 104.68M 98.71M 81.44M
Selling and marketing expenses - - - - -
Gross profit 70.42M 77.01M 133.44M 93.24M 1168.91M
Reconciled depreciation 13.03M 14.15M 14.18M 13.16M 10.87M
Ebit -240.23600M -446.10300M -379.92200M -440.03500M 725.50M
Ebitda -220.53900M -453.79800M -347.45800M -380.54400M 736.37M
Depreciation and amortization 19.70M -7.69500M 32.46M 59.49M 10.87M
Non operating income net other - -29.86400M 18.28M 46.34M 37.57M
Operating income -240.23600M -446.10300M -379.92200M -440.03500M 687.93M
Other operating expenses 332.29M 548.01M 532.84M 554.65M 505.39M
Interest expense 28.91M 47.31M 37.12M 46.35M 42.78M
Tax provision 3.21M 0.56M 0.49M 0.61M 1.41M
Interest income 6.67M 2.57M 18.28M 46.34M 37.57M
Net interest income -22.24400M -44.74400M -18.83600M -0.01900M -5.20700M
Extraordinary items - - - -0.02300M -0.04500M
Non recurring - - - - -
Other items - - - - -
Income tax expense 3.21M 0.56M 0.49M 0.61M 1.41M
Total revenue 92.06M 101.91M 152.91M 114.62M 1193.32M
Total operating expenses 310.66M 523.11M 513.36M 533.28M 480.98M
Cost of revenue 21.64M 24.90M 19.48M 21.37M 24.41M
Total other income expense net -124.74700M -77.17700M -64.02500M -0.01900M -5.20700M
Discontinued operations - - - - -
Net income from continuing ops -368.19800M -523.83700M -444.44000M -440.66700M 681.31M
Net income applicable to common shares -368.19800M -523.83700M -444.44000M -440.66700M 681.31M
Preferred stock and other adjustments - - - - -
Breakdown 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Type yearly yearly yearly yearly yearly
Date 2023-12-31 2022-12-31 2021-12-31 2020-12-31 2019-12-31
Total assets 398.03M 710.60M 1117.19M 1538.77M 1977.36M
Intangible assets - - - - 26.91M
Earning assets - - - - -
Other current assets 8.73M 15.81M 23.33M 18.02M 15.39M
Total liab 267.05M 343.96M 437.68M 461.47M 571.97M
Total stockholder equity 130.99M 366.64M 679.51M 1077.30M 1405.39M
Deferred long term liab - - - - -
Other current liab 22.16M 36.56M 58.01M 79.63M 67.93M
Common stock 0.02M 0.02M 0.02M 0.02M 0.02M
Capital stock 0.02M 0.02M 0.02M 0.02M 0.02M
Retained earnings -3477.24900M -3201.19300M -2832.99500M -2309.15800M -1864.71800M
Other liab - 162.93M 226.75M 209.32M 75.34M
Good will 0.00000M 76.50M 76.50M 76.50M 76.50M
Other assets - 2.25M 2.74M 264.60M 1.01M
Cash 20.16M 88.23M 25.22M 198.96M 96.36M
Cash and equivalents - - - - -
Total current liabilities 51.27M 68.20M 85.20M 115.78M 353.89M
Current deferred revenue - - - 0.09M 5.52M
Net debt 210.24M 43.27M 117.96M -48.66700M 307.58M
Short term debt 19.26M 18.67M 17.44M 13.91M 261.21M
Short long term debt - - - - 248.69M
Short long term debt total 230.40M 131.50M 143.18M 150.29M 403.94M
Other stockholder equity 3608.14M 3574.72M 3516.64M 3388.73M 3271.10M
Property plant equipment - 85.89M 177.53M 59.66M 65.00M
Total current assets 330.70M 545.97M 795.58M 1138.01M 1421.55M
Long term investments 25.82M 0.00000M 64.83M 136.66M 279.12M
Net tangible assets - 290.14M 603.01M 1000.79M 1328.89M
Short term investments 283.45M 416.75M 708.74M 862.94M 1228.50M
Net receivables 2.25M 5.98M 22.49M 38.89M 36.80M
Long term debt - - - - -
Inventory 16.10M 19.20M 15.80M 15.29M 12.66M
Accounts payable 9.85M 12.98M 9.75M 22.14M 19.23M
Total permanent equity - - - - -
Noncontrolling interest in consolidated entity - - - - -
Temporary equity redeemable noncontrolling interests - - - - -
Accumulated other comprehensive income 0.08M -6.90700M -4.15700M -2.29500M -1.00500M
Additional paid in capital - - - - -
Common stock total equity - - 0.02M 0.02M 0.02M
Preferred stock total equity - - - - -
Retained earnings total equity - - -2832.99500M -2309.15800M -1864.71800M
Treasury stock - - - - -
Accumulated amortization - - - - -
Non currrent assets other 4.64M 2.25M 2.74M 1.46M 1.01M
Deferred long term asset charges - - - - -
Non current assets total 67.33M 164.63M 321.61M 400.76M 555.81M
Capital lease obligations 117.78M 131.50M 143.18M 150.29M 155.25M
Long term debt total - - - - -
Breakdown 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Type yearly yearly yearly yearly yearly
Date 2022-12-31 2021-12-31 2020-12-31 2019-12-31 2018-12-31
Investments 365.83M 217.77M 503.47M 233.17M -1368.33000M
Change to liabilities 2.04M -12.29500M 15.72M 18.85M 34.14M
Total cashflows from investing activities 365.83M 202.78M 496.21M 206.89M -1379.93600M
Net borrowings - - -250.00000M -250.00000M -250.00000M
Total cash from financing activities 1.51M 36.24M -80.35400M 23.36M 851.97M
Change to operating activities -14.66100M -22.66900M 20.56M 20.16M 1.51M
Net income -368.19800M -523.83700M -444.44000M -440.66700M 681.31M
Change in cash 63.01M -173.73700M 102.59M -98.54200M 190.14M
Begin period cash flow 25.22M 198.96M 96.36M 194.91M 4.76M
End period cash flow 88.23M 25.22M 198.96M 96.36M 194.91M
Total cash from operating activities -304.00700M -412.66000M -313.28700M -328.68100M 718.21M
Issuance of capital stock - - 0.00000M 0.00000M 790.23M
Depreciation 13.03M 14.15M 14.18M 13.16M 10.87M
Other cashflows from investing activities - - - 233.17M 2.63M
Dividends paid - - - - -
Change to inventory -3.40100M -0.50900M -2.62700M -1.28400M -0.65500M
Change to account receivables 16.51M 12.40M 1.91M 6.41M -25.50500M
Sale purchase of stock - 33.24M 23.40M 23.36M 851.97M
Other cashflows from financing activities 1.51M 36.24M 169.65M 23.36M 61.73M
Change to netincome 50.67M 120.11M 75.97M 88.54M 75.99M
Capital expenditures 5.68M 14.99M 7.26M 26.29M 14.24M
Change receivables - 12.40M 1.91M 6.41M -25.50500M
Cash flows other operating - 30.19M 26.00M -13.67900M -57.93500M
Exchange rate changes - - - - -
Cash and cash equivalents changes - -173.64500M 102.57M -98.44000M 190.24M
Change in working capital 0.49M -23.07600M 16.71M 21.69M -39.00600M
Stock based compensation 57.32M 94.67M 94.26M 99.80M 88.10M
Other non cash items -9.35900M 17.41M -14.35300M -22.65300M -23.06400M
Free cash flow -309.68300M -427.64900M -320.54500M -354.96600M 703.98M

Peer Comparison

Sector: Healthcare Industry: Biotechnology

Company Change (USD) Price (USD) Trailing PE (x) Forward PE (x) Price Sales TTM (x) Price to Book Value (x) Enterprise Value to Revenue (x) Enterprise Value to EBITDA (x)
NKTR
Nektar Therapeutics		 -1.15 11.51% 8.84 - - 3.40 2.34 1.34 -0.4969
NVO
Novo Nordisk A/S		 0.82 1.10% 75.45 41.58 31.15 2.13 32.99 2.11 4.70
NONOF
Novo Nordisk A/S		 1.68 2.29% 75.10 41.06 31.25 2.08 33.11 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc		 -2.96 0.66% 447.54 29.67 24.33 10.38 5.83 9.33 20.00
REGN
Regeneron Pharmaceuticals Inc		 20.10 4.08% 513.32 29.07 20.12 7.57 3.82 6.95 19.42

Reports Covered

Stock Research & News

View All

Profile

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.

Nektar Therapeutics

455 Mission Bay Boulevard South, San Francisco, CA, United States, 94158

Key Executives

Name Title Year Born
Mr. Howard W. Robin CEO, Pres & Director 1953
Mr. Mark A. Wilson Chief Legal Officer & Sec. 1972
Dr. Jonathan Zalevsky Ph.D. Sr. VP & Chief R&D Officer 1975
Mr. John P. Northcott Strategic Consulting Advisor 1978
Ms. Jillian B. Thomsen Chief Financial Officer 1966
Mr. Robert Bacci Sr. VP of HR & Facilities Operations NA
Ms. Jennifer Ruddock Chief Bus. Officer NA
Dr. Mary Tagliaferri L.Ac., M.D. Chief Devel. Officer 1966
Dr. Brian L. Kotzin M.D. Chief Medical Officer 1949
Dr. Kevin Brodbeck Ph.D. Sr. VP of Technical Operations NA

Disclaimer - This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes. This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API. Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.